Aslan, Nanyang in antibody fragment deal

Cancer company Aslan Pharmaceuticals Ltd. (Singapore) said it partnered with Nanyang Technological University to develop Modybodies, which are stabilized heavy chain mAb fragments, against three targets of Aslan's choice. Aslan said the fragments are designed for higher tissue penetration due to their small size.

Aslan has an exclusive option to gain global rights to the programs for pre-negotiated, undisclosed terms. The company expects the first clinical study of a Modybody to begin in 2018. ...